Sugi Predict

Sugi Predict / Compounds / SCHEMBL22291660

SCHEMBL22291660

SCHEMBL22291660

Cc1cc(Cl)ncc1C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 7/20 0.59
▸ SIRT3 Q9NTG7 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ GABRP O00591 1/20 0.46
▸ GABRD O14764 1/20 0.46
▸ GABRA1 P14867 1/20 0.46
▸ GABRB1 P18505 1/20 0.46
▸ GABRG2 P18507 1/20 0.46
▸ GABRB3 P28472 1/20 0.46
▸ GABRA5 P31644 1/20 0.46
▸ GABRA3 P34903 1/20 0.46
▸ GABRA2 P47869 1/20 0.46
▸ GABRB2 P47870 1/20 0.46
▸ GABRA4 P48169 1/20 0.46
▸ GABRE P78334 1/20 0.46
▸ GABRA6 Q16445 1/20 0.46
▸ GABRG1 Q8N1C3 1/20 0.46
▸ GABRG3 Q99928 1/20 0.46
▸ GABRQ Q9UN88 1/20 0.46
▸ SIRT6 Q8N6T7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096979 1.00 NNMT (0.59) NNMTSIRT3TDP1GABRPGABRD
SCHEMBL15547132 0.84 GABRP (0.44) NNMTGABRPGABRDGABRA1GABRB1
SCHEMBL3752864 0.82 GABRP (0.61) NNMTGABRPGABRDGABRA1GABRB1
SCHEMBL15713423 0.82 KCNQ3 (0.43) NNMTTDP1GABRPGABRDGABRA1
SCHEMBL30414922 0.82 KCNQ3 (0.43) NNMTTDP1GABRPGABRDGABRA1
SCHEMBL30197143 0.80 NNMT (0.62) NNMTSIRT3TDP1GABRPGABRD
SCHEMBL29799541 0.80 NNMT (0.61) NNMTSIRT6SLC2A1MKNK1MKNK2
SCHEMBL384113 0.80 NNMT (0.61) NNMTSIRT6SLC2A1MKNK1MKNK2
SCHEMBL5009904 0.80 NNMT (0.62) NNMTSIRT3TDP1GABRPGABRD
SCHEMBL17362420 0.78 SIRT6 (0.47) NNMTTDP1GABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4096651-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2026-05-27 — — EP disclosed
US-12391686-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-19 — — US disclosed
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 — — EP disclosed
CN-119730846-A Kinase modulators and methods of use thereof 神经元23公司 2025-03-28 — — CN disclosed
US-20250085300-A1 STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS FOGHORN THERAPEUTICS INC. 2025-03-13 — — US disclosed
US-20240325370-A1 THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 FOGHORN THERAPEUTICS INC. 2024-10-03 — — US disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 — — WO disclosed
CN-115052594-B Compounds and uses thereof 福宏治疗公司 2024-07-16 — — CN disclosed
US-20240190894-A1 CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME FOGHORN THERAPEUTICS INC. 2024-06-13 — — US disclosed
US-20240166668-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-05-23 — — US disclosed
WO-2022025880-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-02-03 — — WO disclosed
WO-2022025880-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-02-03 — — WO disclosed
CN-113874016-A Compound and use thereof 福宏治疗公司 2021-12-31 — — CN disclosed
EP-3917526-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 — — EP disclosed
WO-2021155225-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
WO-2021155225-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed
US-20210230190-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-07-29 — — US disclosed
US-20210230190-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-07-29 — — US disclosed
WO-2020160192-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed
WO-2020160192-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250085300-A1 STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS GCDH, GLRX3, GRHPR NNMT 1339/4885SIRT3 1100/4885TDP1 3506/4885
US-20240190894-A1 CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME CS, SMARCC2, SMARCC1 NNMT 4418/4885SIRT3 1069/4885TDP1 1890/4885
US-12391686-B2 Compounds and uses thereof VHL, TFEB, BECN1 NNMT 519/4885SIRT3 1294/4885TDP1 1305/4885
US-20240166668-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NNMT 512/4885SIRT3 2059/4885TDP1 725/4885
US-20210230190-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NNMT 512/4885SIRT3 2059/4885TDP1 725/4885
US-20240325370-A1 THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 BRD9, SND1, SBDS NNMT 4276/4885SIRT3 4450/4885TDP1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.